Skip to content
← Back to S&P 500 Dashboard

CRL

N/A

Charles River Laboratories Inte

Healthcare · Rank #494 · Analyzed Jul 13, 2026

$233.41

Current Price

⚠️ Unverified — fails data-quality checks

This ticker did not clear our Definition of Done, so its valuation is shown for transparency but should not be trusted:

  • • Intrinsic value not computed
  • • Insufficient data to rate
  • • <2 valuation methods computed

$0.00

Intrinsic Value

-85.7%

Upside/Downside

0/10

Score

0.5/5

Quality

Analysis Summary

Valuation Consensus0/1 methods agree
Quality Score0.5/5.0
Framework RatingINSUFFICIENT DATA
Price vs Intrinsic ValueOvervalued by 85.7%

Fair Value Range

Low$33.28
Base (IV)$0.00
High$33.28

Entry Points

Conservative$23.30
Moderate$33.28
Aggressive$23.30

⚠️ Warnings

  • DCF discarded: negative profit margins
  • Insufficient data: fewer than 2 valuation methods

Quality & Moat Breakdown

Return on Equity-5.9% → 0/1.0
Debt LevelD/E 103 → 0/1.0
Revenue QualityGrowth -1.1%, margin Δ+0.2% +recovery → 0.5/1.0
Moat Strength1.0/5 → 0/1.0
Profit Margins-4.6% → 0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.